Immunotherapy of Fungal Infections

References

• Allendoerfer R, Magee DM, Deepe GS Jr, Graybill JR. (1993). Transfer of protective immunity in murine histoplasmosis by a CD4+ T-cell clone. Infect Immun, 61, 714–18
   PubMed Web of Science ®Google Scholar
• Alviano DS, Franzen AJ, Travassos LR, et al. (2004). Melanin from Fonsecaea pedrosoi induces production of human antifungal antibodies and enhances the antimicrobial efficacy of phagocytes. Infect Immun, 72, 229–37
   PubMed Web of Science ®Google Scholar
• Assis-Marques MA, Oliveira AF, Ruas LP, et al. (2015). Saccharomyces cerevisiae expressing Gp43 protects mice against Paracoccidioides brasiliensis infection. PloS One, 10, e0120201
   PubMed Web of Science ®Google Scholar
• Bader T, Bodendorfer B, Schroppel K, Morschhauser J. (2003). Calcineurin is essential for virulence in Candida albicans. Infect Immun, 71, 5344–54
   PubMed Web of Science ®Google Scholar
• Badiee P, Hashemizadeh Z. (2014). Opportunistic invasive fungal infections: Diagnosis & clinical management. Indian J Med Res, 139, 195–204
   PubMed Web of Science ®Google Scholar
• Baranger K, Zani ML, Chandenier J, et al. (2008). The antibacterial and antifungal properties of trappin-2 (pre-elafin) do not depend on its protease inhibitory function. FEBS J, 275, 2008–20
   PubMed Web of Science ®Google Scholar
• Bayry J, Aimanianda V, Guijarro JI, et al. (2012). Hydrophobins–unique fungal proteins. PLoS Pathog, 8, e1002700
   PubMed Web of Science ®Google Scholar
• Bedke T, Iannitti RG, De Luca A, et al. (2014). Distinct and complementary roles for Aspergillus fumigatus-specific Tr1 and Foxp3+ regulatory T cells in humans and mice. Immunol Cell Biol, 92, 659–70
   PubMed Web of Science ®Google Scholar
• Beenhouwer DO, Yoo EM, Lai CW, et al. (2007). Human immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection. Infect Immun, 75, 1424–35
   PubMed Web of Science ®Google Scholar
• Bennett JW, Klich M. (2003). Mycotoxins. Clin Microbiol Rev, 16, 497–516
   PubMed Web of Science ®Google Scholar
• Bhagwat SP, Wright TW, Gigliotti F. (2010). Anti-CD3 antibody decreases inflammation and improves outcome in a murine model of Pneumocystis pneumonia. J Immunol, 184, 497–502
   PubMed Web of Science ®Google Scholar
• Bhatia S, Tykodi SS, Thompson JA. (2009). Treatment of metastatic melanoma: An overview. Oncology, 23, 488–96
   PubMed Web of Science ®Google Scholar
• Blankenship JR, Wormley FL, Boyce MK, et al. (2003). Calcineurin is essential for Candida albicans survival in serum and virulence. Eukaryot Cell, 2, 422–30
   PubMed Web of Science ®Google Scholar
• Bouzani M, Ok M, McCormick A, et al. (2011). Human NK cells display important antifungal activity against Aspergillus fumigatus, which is directly mediated by IFN-gamma release. J Immunol, 187, 1369–76
   PubMed Web of Science ®Google Scholar
• Bowdish DM, Davidson DJ, Scott MG, Hancock RE. (2005). Immunomodulatory activities of small host defense peptides. Antimicrob Agents Chemother, 49, 1727–32
   PubMed Web of Science ®Google Scholar
• Bozza S, Clavaud C, Giovannini G, et al. (2009). Immune sensing of Aspergillus fumigatus proteins, glycolipids, and polysaccharides and the impact on Th immunity and vaccination. J Immunol, 183, 2407–14
   PubMed Web of Science ®Google Scholar
• Bozza S, Gaziano R, Lipford GB, et al. (2002). Vaccination of mice against invasive aspergillosis with recombinant Aspergillus proteins and CpG oligodeoxynucleotides as adjuvants. Microbes Infect, 4, 1281–90
   PubMed Web of Science ®Google Scholar
• Braga CJ, Rittner GM, Munoz Henao JE, et al. (2009). Paracoccidioides brasiliensis vaccine formulations based on the gp43-derived P10 sequence and the Salmonella enterica FliC flagellin. Infect Immun, 77, 1700–7
   PubMed Web of Science ®Google Scholar
• Brena S, Omaetxebarria MJ, Elguezabal N, et al. (2007). Fungicidal monoclonal antibody C7 binds to Candida albicans Als3. Infect Immun, 75, 3680–2
   PubMed Web of Science ®Google Scholar
• Bromuro C, Romano M, Chiani P, et al. (2010). Beta-glucan-CRM197 conjugates as candidates antifungal vaccines. Vaccine, 28, 2615–23
   PubMed Web of Science ®Google Scholar
• Bryan RA, Jiang Z, Huang X, et al. (2009). Radioimmunotherapy is effective against high-inoculum Cryptococcus neoformans infection in mice and does not select for radiation-resistant cryptococcal cells. Antimicrob Agents Chemother, 53, 1679–82
   PubMed Web of Science ®Google Scholar
• Bryan RA, Jiang Z, Morgenstern A, et al. (2013). Radioimmunotherapy of Cryptococcus neoformans spares bystander mammalian cells. Future Microbiol, 8, 1081–9
   PubMed Web of Science ®Google Scholar
• Buissa-Filho R, Puccia R, Marques AF, et al. (2008). The monoclonal antibody against the major diagnostic antigen of Paracoccidioides brasiliensis mediates immune protection in infected BALB/c mice challenged intratracheally with the fungus. Infect Immun, 76, 3321–8
   PubMed Web of Science ®Google Scholar
• Calcedo R, Ramirez-Garcia A, Abad A, et al. (2012). Phosphoglycerate kinase and fructose bisphosphate aldolase of Candida albicans as new antigens recognized by human salivary IgA. Rev Iberoam Micol, 29, 172–4
   PubMed Web of Science ®Google Scholar
• Callejas CA, Douglas RG. (2013). Fungal rhinosinusitis: What every allergist should know. Clin Exp Allergy, 43, 835–49
   PubMed Web of Science ®Google Scholar
• Capilla J, Clemons KV, Liu M, et al. (2009). Saccharomyces cerevisiae as a vaccine against coccidioidomycosis. Vaccine, 27, 3662–8
   PubMed Web of Science ®Google Scholar
• Casadevall A, Pirofski LA. (1999). Host-pathogen interactions: Redefining the basic concepts of virulence and pathogenicity. Infect Immun, 67, 3703–13
   PubMed Web of Science ®Google Scholar
• Casadevall A, Pirofski LA. (2007). Antibody-mediated protection through cross-reactivity introduces a fungal heresy into immunological dogma. Infect Immun, 75, 5074–8
   PubMed Web of Science ®Google Scholar
• Casadevall A, Pirofski LA. (2012). Immunoglobulins in defense, pathogenesis, and therapy of fungal diseases. Cell Host Microbe, 11, 447–56
   PubMed Web of Science ®Google Scholar
• Casadevall A. (1995). Antibody immunity and invasive fungal infections. Infect Immun, 63, 4211–18
   PubMed Web of Science ®Google Scholar
• Cenci E, Bistoni F, Mencacci A, et al. (2004). A synthetic peptide as a novel anticryptococcal agent. Cell Microbiol, 6, 953–61
   PubMed Web of Science ®Google Scholar
• Cenci E, Mencacci A, Bacci A, et al. (2000). T cell vaccination in mice with invasive pulmonary aspergillosis. J Immunol, 165, 381–8
   PubMed Web of Science ®Google Scholar
• Cenci E, Mencacci A, Spreca A, et al. (2002). Protection of killer antiidiotypic antibodies against early invasive aspergillosis in a murine model of allogeneic T-cell-depleted bone marrow transplantation. Infect Immun, 70, 2375–82
   PubMed Web of Science ®Google Scholar
• Cenci E, Pericolini E, Mencacci A, et al. (2006). Modulation of phenotype and function of dendritic cells by a therapeutic synthetic killer peptide. J Leukocyte Biol, 79, 40–5
   PubMed Web of Science ®Google Scholar
• Chang HH, Lee NY, Ko WC, et al. (2010). Voriconazole inhibition of tacrolimus metabolism in a kidney transplant recipient with fluconazole-resistant cryptococcal meningitis. Int J Infect Dis, 14, e348–50
   PubMed Web of Science ®Google Scholar
• Chang KC, Burnham CA, Compton SM, et al. (2013). Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis. Crit Care, 17, R85
   PubMed Web of Science ®Google Scholar
• Chaturvedi AK, Hameed RS, Wozniak KL, et al. (2014). Vaccine-mediated immune responses to experimental pulmonary Cryptococcus gattii infection in mice. PloS One, 9, e104316
   Google Scholar
• Chaturvedi AK, Kavishwar A, Shiva Keshava GB, Shukla PK. (2005). Monoclonal immunoglobulin G1 directed against Aspergillus fumigatus cell wall glycoprotein protects against experimental murine aspergillosis. Clin Diagn Lab Immunol, 12, 1063–8
   PubMedGoogle Scholar
• Chen HX, Cleck JN. (2009). Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol, 6, 465–77
   PubMed Web of Science ®Google Scholar
• Chiou CC, Groll AH, Walsh TJ. (2000). New drugs and novel targets for treatment of invasive fungal infections in patients with cancer. Oncologist, 5, 120–35
   PubMedGoogle Scholar
• Chirch LM, Cataline PR, Dieckhaus KD, Grant-Kels JM. (2014). Proactive infectious disease approach to dermatologic patients who are taking tumor necrosis factor-alfa antagonists: Part II. Screening for patients on tumor necrosis factor-alfa antagonists. J Am Acad Dermatol, 71, 11 e11–7; quiz 18–20
   Google Scholar
• Clipstone NA, Crabtree GR. (1992). Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature, 357, 695–7
   PubMed Web of Science ®Google Scholar
• Clipstone NA, Crabtree GR. (1993). Calcineurin is a key signaling enzyme in T lymphocyte activation and the target of the immunosuppressive drugs cyclosporin A and FK506. Ann N Y Acad Sci, 696, 20–30
   PubMed Web of Science ®Google Scholar
• Cruz MC, Fox DS, Heitman J. (2001). Calcineurin is required for hyphal elongation during mating and haploid fruiting in Cryptococcus neoformans. EMBO J, 20, 1020–32
   PubMed Web of Science ®Google Scholar
• Dadachova E, Bryan RA, Apostolidis C, et al. (2006). Interaction of radiolabeled antibodies with fungal cells and components of the immune system in vitro and during radioimmunotherapy for experimental fungal infection. J Infect Dis, 193, 1427–36
   PubMed Web of Science ®Google Scholar
• Dadachova E, Casadevall A. (2006). Treatment of infection with radiolabeled antibodies. Q J Nucl Med Mol Imaging, 50, 193–204
   PubMed Web of Science ®Google Scholar
• Dadachova E, Casadevall A. (2009). Radioimmunotherapy of infectious diseases. Semin Nucl Med, 39, 146–53
   PubMed Web of Science ®Google Scholar
• da Silva MB, Marques AF, Nosanchuk JD, et al. (2006). Melanin in the dimorphic fungal pathogen Paracoccidioides brasiliensis: Effects on phagocytosis, intracellular resistance and drug susceptibility. Microbes Infect, 8, 197–205
   PubMed Web of Science ®Google Scholar
• Datta K, Lees A, Pirofski LA. (2008). Therapeutic efficacy of a conjugate vaccine containing a peptide mimotope of cryptococcal capsular polysaccharide glucuronoxylomannan. Clin Vaccine Immunol CVI, 15, 1176–87
   PubMed Web of Science ®Google Scholar
• de Bastos Ascenco Soares R, Gomez FJ, de Almeida Soares CM, Deepe GS, Jr. (2008). Vaccination with heat shock protein 60 induces a protective immune response against experimental Paracoccidioides brasiliensis pulmonary infection. Infect Immun, 76, 4214–21
   PubMed Web of Science ®Google Scholar
• De Bernardis F, Boccanera M, Adriani D, et al. (1997). Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats. Infect Immun, 65, 3399–405
   PubMed Web of Science ®Google Scholar
• De Bernardis F, Liu H, O’Mahony R, et al. (2007). Human domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidiasis. J Infect Dis, 195, 149–57
   PubMed Web of Science ®Google Scholar
• Delsing CE, Gresnigt MS, Leentjens J, et al. (2014). Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: A case series. BMC Infect Dis, 14, 166
   PubMed Web of Science ®Google Scholar
• De Luca AJ, Walsh TJ. (2000). Antifungal peptides: Origin, activity, and therapeutic potential. Rev iberoam Micol, 17, 116–20
   PubMedGoogle Scholar
• de Mattos Grosso D, de Almeida SR, Mariano M, Lopes JD. (2003). Characterization of gp70 and anti-gp70 monoclonal antibodies in Paracoccidioides brasiliensis pathogenesis. Infect Immun, 71, 6534–42
   PubMed Web of Science ®Google Scholar
• Denning DW. (2003). Echinocandin antifungal drugs. Lancet, 362, 1142–51
   PubMed Web of Science ®Google Scholar
• Devi SJ. (1996). Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model. Vaccine, 14, 841–4
   PubMed Web of Science ®Google Scholar
• Donini M, Lico C, Baschieri S, Conti S, et al. (2005). Production of an engineered killer peptide in Nicotiana benthamiana by using a potato virus X expression system. Appl Environ Microbiol, 71, 6360–7
   PubMed Web of Science ®Google Scholar
• Dromer F, Charreire J, Contrepois A, et al. (1987a). Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody. Infect Immun, 55, 749–52
   PubMed Web of Science ®Google Scholar
• Dromer F, Salamero J, Contrepois A, et al. (1987b). Production, characterization, and antibody specificity of a mouse monoclonal antibody reactive with Cryptococcus neoformans capsular polysaccharide. Infect Immun, 55, 742–8
   PubMed Web of Science ®Google Scholar
• Edgerton M, Koshlukova SE. (2000). Salivary histatin 5 and its similarities to the other antimicrobial proteins in human saliva. Adv Dental Res, 14, 16–21
   PubMedGoogle Scholar
• Felonato M, Pina A, de Araujo EF, et al. (2012). Anti-CD25 treatment depletes Treg cells and decreases disease severity in susceptible and resistant mice infected with Paracoccidioides brasiliensis. PloS One, 7, e51071
   PubMed Web of Science ®Google Scholar
• Feng Y, Guo S, Jiang T, et al. (2011). Active immunization against Pneumocystis carinii with p55-v3 DNA vaccine in rats. Can J Microbiol, 57, 375–81
   PubMed Web of Science ®Google Scholar
• Fernandes VC, Martins EM, Boeloni JN, et al. (2011). Additive effect of rPb27 immunization and chemotherapy in experimental paracoccidioidomycosis. PloS One, 6, e17885
   Google Scholar
• Fleuridor R, Zhong Z, Pirofski L. (1998). A human IgM monoclonal antibody prolongs survival of mice with lethal cryptococcosis. J Infect Dis, 178, 1213–16
   PubMed Web of Science ®Google Scholar
• Franco-Paredes C, Womack T, Bohlmeyer T, et al. (2015). Management of Cryptococcus gattii meningoencephalitis. Lancet Infect Dis, 15, 348–55
   PubMed Web of Science ®Google Scholar
• Gaundar SS, Clancy L, Blyth E, et al. (2012). Robust polyfunctional T-helper 1 responses to multiple fungal antigens from a cell population generated using an environmental strain of Aspergillus fumigatus. Cytotherapy, 14, 1119–30
   PubMed Web of Science ®Google Scholar
• Georgopapadakou NH, Walsh TJ. (1996). Antifungal agents: Chemotherapeutic targets and immunologic strategies. Antimicrob Agents Chemother, 40, 279–91
   PubMed Web of Science ®Google Scholar
• Gigliotti F, Garvy BA, Harmsen AG. (1996). Antibody-mediated shift in the profile of glycoprotein A phenotypes observed in a mouse model of Pneumocystis carinii pneumonia. Infect Immun, 64, 1892–9
   PubMed Web of Science ®Google Scholar
• Gigliotti F, Haidaris CG, Wright TW, Harmsen AG. (2002). Passive intranasal monoclonal antibody prophylaxis against murine Pneumocystis carinii pneumonia. Infect Immun, 70, 1069–74
   PubMed Web of Science ®Google Scholar
• Gigliotti F, Hughes WT. (1988). Passive immunoprophylaxis with specific monoclonal antibody confers partial protection against Pneumocystis carinii pneumonitis in animal models. J Clin Invest, 81, 1666–8
   PubMed Web of Science ®Google Scholar
• Gomez FJ, Allendoerfer R, Deepe GS, Jr. (1995). Vaccination with recombinant heat shock protein 60 from Histoplasma capsulatum protects mice against pulmonary histoplasmosis. Infect Immun, 63, 2587–95
   PubMed Web of Science ®Google Scholar
• Graybill JR, Bocanegra R, Najvar LK, et al. (1998). Granulocyte colony-stimulating factor and azole antifungal therapy in murine aspergillosis: Role of immune suppression. Antimicrob Agents Chemother, 42, 2467–73
   PubMed Web of Science ®Google Scholar
• Grigull L, Beilken A, Schmid H, et al. (2006a). Secondary prophylaxis of invasive fungal infections with combination antifungal therapy and G-CSF-mobilized granulocyte transfusions in three children with hematological malignancies. Support Care Cancer, 14, 783–6
   PubMed Web of Science ®Google Scholar
• Grigull L, Pulver N, Goudeva L, et al. (2006b). G-CSF mobilised granulocyte transfusions in 32 paediatric patients with neutropenic sepsis. Support Care Cancer, 14, 910–16
   PubMed Web of Science ®Google Scholar
• Grubbs JA, Baddley JW. (2014). Pneumocystis jirovecii pneumonia in patients receiving tumor-necrosis-factor-inhibitor therapy: Implications for chemoprophylaxis. Curr Rheumatol Rep, 16, 445
   PubMed Web of Science ®Google Scholar
• Guimaraes AJ, Frases S, Gomez FJ, et al. (2009). Monoclonal antibodies to heat shock protein 60 alter the pathogenesis of Histoplasma capsulatum. Infect Immun, 77, 1357–67
   PubMed Web of Science ®Google Scholar
• Hamad M. (2008). Antifungal immunotherapy and immunomodulation: A double-hitter approach to deal with invasive fungal infections. Scand J Immunol, 67, 533–43
   PubMed Web of Science ®Google Scholar
• Hamad M. (2012). Universal fungal vaccines: Could there be light at the end of the tunnel? HumVaccinImmunother, 8, 1758–63
   Google Scholar
• Han DM, Wang ZD, Ding L, et al. (2014). Effect of umbilical cord MSC infusion on the pulmonary infection in haploidentical hematopoietic stem cell transplantation. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 22, 1084–8
   PubMedGoogle Scholar
• Han Y, Cutler JE. (1995). Antibody response that protects against disseminated candidiasis. Infect Immun, 63, 2714–19
   PubMed Web of Science ®Google Scholar
• Han Y, Morrison RP, Cutler JE. (1998). A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection. Infect Immun, 66, 5771–6
   PubMed Web of Science ®Google Scholar
• Hansel TT, Kropshofer H, Singer T, et al. (2010). The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov, 9, 325–38
   PubMed Web of Science ®Google Scholar
• Helmerhorst EJ, Troxler RF, Oppenheim FG. (2001). The human salivary peptide histatin 5 exerts its antifungal activity through the formation of reactive oxygen species. Proc Natl Acad Sci U S A, 98, 14637–42
   PubMed Web of Science ®Google Scholar
• Herr RA, Hung CY, Cole GT. (2007). Evaluation of two homologous proline-rich proteins of Coccidioides posadasii as candidate vaccines against coccidioidomycosis. Infect Immun, 75, 5777–87
   PubMed Web of Science ®Google Scholar
• Hodgetts S, Nooney L, Al-Akeel R, et al. (2008). Efungumab and caspofungin: Pre-clinical data supporting synergy. J Antimicrob Chemother, 61, 1132–9
   PubMed Web of Science ®Google Scholar
• Hoyt TR, Dobrinen E, Kochetkova I, Meissner N. (2015). B cells modulate systemic responses to Pneumocystis murina lung infection and protect on-demand hematopoiesis via T cell-independent innate mechanisms when type I interferon signaling is absent. Infect Immun, 83, 743–58
   PubMed Web of Science ®Google Scholar
• Hung CY, Hurtgen BJ, Bellecourt M, et al. (2012). An agonist of human complement fragment C5a enhances vaccine immunity against Coccidioides infection. Vaccine, 30, 4681–90
   PubMed Web of Science ®Google Scholar
• Hurtgen BJ, Hung CY, Ostroff GR, et al. (2012). Construction and evaluation of a novel recombinant T cell epitope-based vaccine against Coccidioidomycosis. Infect Immun, 80, 3960–74
   PubMed Web of Science ®Google Scholar
• Ibrahim el SM, Rahman AK, Isoda R, et al. (2008). In vitro and in vivo effectiveness of egg yolk antibody against Candida albicans (anti-CA IgY). Vaccine, 26, 2073–80
   PubMed Web of Science ®Google Scholar
• Ito JI, Lyons JM, Hong TB, et al. (2006). Vaccinations with recombinant variants of Aspergillus fumigatus allergen Asp f 3 protect mice against invasive aspergillosis. Infect Immun, 74, 5075–84
   PubMed Web of Science ®Google Scholar
• Jarvis JN, Meintjes G, Rebe K, et al. (2012). Adjunctive interferon-gamma immunotherapy for the treatment of HIV-associated cryptococcal meningitis: A randomized controlled trial. AIDS, 26, 1105–13
   PubMed Web of Science ®Google Scholar
• Jiang C, Magee DM, Cox RA. (1999). Construction of a single-chain interleukin-12-expressing retroviral vector and its application in cytokine gene therapy against experimental coccidioidomycosis. Infect Immun, 67, 2996–3001
   PubMed Web of Science ®Google Scholar
• Jiang Z, Kullberg BJ, van der Lee H, et al. (2008). Effects of hydrophobicity on the antifungal activity of alpha-helical antimicrobial peptides. Chem BiolDrug Design, 72, 483–95
   PubMed Web of Science ®Google Scholar
• Kanu A, Patel K. (2008). Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with anti-IgE antibody (omalizumab). Pediatric Pulmonol, 43, 1249–51
   PubMed Web of Science ®Google Scholar
• Khanna N, Stuehler C, Conrad B, et al. (2011). Generation of a multipathogen-specific T-cell product for adoptive immunotherapy based on activation-dependent expression of CD154. Blood, 118, 1121–31
   PubMed Web of Science ®Google Scholar
• Kleinnijenhuis J, Quintin J, Preijers F, et al. (2014). BCG-induced trained immunity in NK cells: Role for non-specific protection to infection. Clin Immunol, 155, 213–19
   PubMed Web of Science ®Google Scholar
• Kolaczkowska A, Kolaczkowski M, Sokolowska A, et al. (2010). The antifungal properties of chicken egg cystatin against Candida yeast isolates showing different levels of azole resistance. Mycoses, 53, 314–20
   PubMed Web of Science ®Google Scholar
• Konig B, Petersen A, Bellinghausen I, et al. (2007). Human dendritic cells transfected with allergen-DNA stimulate specific immunoglobulin G4 but not specific immunoglobulin E production of autologous B cells from atopic individuals in vitro. Immunology, 122, 239–46
   PubMed Web of Science ®Google Scholar
• Kumaresan PR, Manuri PR, Albert ND, et al. (2014). Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection. Proc Natl Acad Sci U S A, 111, 10660–5
   PubMed Web of Science ®Google Scholar
• Kuypers DR. (2009). Immunotherapy in elderly transplant recipients: A guide to clinically significant drug interactions. Drugs Aging, 26, 715–37
   PubMed Web of Science ®Google Scholar
• Larsen RA, Pappas PG, Perfect J, et al. (2005). Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrob Agents Chemother, 49, 952–8
   PubMed Web of Science ®Google Scholar
• Levitz SM, Dupont MP. (1993). Phenotypic and functional characterization of human lymphocytes activated by interleukin-2 to directly inhibit growth of Cryptococcus neoformans in vitro. J Clin Invest, 91, 1490–8
   PubMed Web of Science ®Google Scholar
• Li W, Fu M, An JG, et al. (2007). Host defence against C. albicans infections in IgH transgenic mice with V(H) derived from a natural anti-keratin antibody. Cell Microbiol, 9, 306–15
   PubMed Web of Science ®Google Scholar
• Lin JS, Yang CW, Wang DW, Wu-Hsieh BA. (2005). Dendritic cells cross-present exogenous fungal antigens to stimulate a protective CD8 T cell response in infection by Histoplasma capsulatum. J Immunol, 174, 6282–91
   PubMed Web of Science ®Google Scholar
• Liu M, Clemons KV, Bigos M, et al. (2011). Immune responses induced by heat killed Saccharomyces cerevisiae: A vaccine against fungal infection. Vaccine, 29, 1745–53
   PubMed Web of Science ®Google Scholar
• Lucas M, Lee M, Lortan J, et al. (2010). Infection outcomes in patients with common variable immunodeficiency disorders: Relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol, 125, 1354–60 e1354
   PubMed Web of Science ®Google Scholar
• Luo G, Ibrahim AS, French SW, et al. (2011). Active and passive immunization with rHyr1p-N protects mice against hematogenously disseminated candidiasis. PloS One, 6, e25909
   Web of Science ®Google Scholar
• Lyman CA, Gonzalez C, Schneider M, et al. (1999). Effects of the hematoregulatory peptide SK&F 107647 alone and in combination with amphotericin B against disseminated candidiasis in persistently neutropenic rabbits. Antimicrob Agents Chemother, 43, 2165–9
   PubMed Web of Science ®Google Scholar
• Macura AB, Macura-Biegun A, Pawlik B. (2003). Susceptibility to fungal infections of nails in patients with primary antibody deficiency. Comp Immunol Microbiol Infect Dis, 26, 223–32
   PubMed Web of Science ®Google Scholar
• Magliani W, Conti S, Giovati L, et al. (2012). Antibody Peptide based antifungal immunotherapy. Front Microbiol, 3, 190
   PubMed Web of Science ®Google Scholar
• Maitta RW, Datta K, Chang Q, et al. (2004). Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles. Infect Immun, 72, 4810–18
   PubMed Web of Science ®Google Scholar
• Malphettes M, Gerard L, Galicier L, et al. (2015). Good syndrome: An adult-onset immunodeficiency remarkable for its high incidence of invasive infections and autoimmune complications. Clin Infect Dis, 61, e13–9
   PubMed Web of Science ®Google Scholar
• Manfredi M, McCullough MJ, Conti S, et al. (2005). In vitro activity of a monoclonal killer anti-idiotypic antibody and a synthetic killer peptide against oral isolates of Candida spp. differently susceptible to conventional antifungals. Oral Microbiol Immunol, 20, 226–32
   PubMedGoogle Scholar
• Manfredi M, Merigo E, Salati A, et al. (2007). In vitro candidacidal activity of a synthetic killer decapeptide (KP) against Candida albicans cells adhered to resin acrylic discs. J Oral Pathol Med, 36, 468–71
   PubMed Web of Science ®Google Scholar
• Mansour MK, Yauch LE, Rottman JB, Levitz SM. (2004). Protective efficacy of antigenic fractions in mouse models of cryptococcosis. Infect Immun, 72, 1746–54
   PubMed Web of Science ®Google Scholar
• Marques AF, da Silva MB, Juliano MA, et al. (2006). Peptide immunization as an adjuvant to chemotherapy in mice challenged intratracheally with virulent yeast cells of Paracoccidioides brasiliensis. Antimicrob Agents Chemother, 50, 2814–19
   PubMed Web of Science ®Google Scholar
• Marr KA, Datta K, Pirofski LA, Barnes R. (2012). Cryptococcus gattii infection in healthy hosts: A sentinel for subclinical immunodeficiency? Clin Infect Dis, 54, 153–4
   PubMed Web of Science ®Google Scholar
• Matsuzaki G, Umemura M. (2007). Interleukin-17 as an effector molecule of innate and acquired immunity against infections. Microbiol Immunol, 51, 1139–47
   PubMed Web of Science ®Google Scholar
• Matthews R, Hodgetts S, Burnie J. (1995). Preliminary assessment of a human recombinant antibody fragment to hsp90 in murine invasive candidiasis. J Infect Dis, 171, 1668–71
   PubMed Web of Science ®Google Scholar
• Matthews RC, Rigg G, Hodgetts S, et al. (2003). Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. Antimicrob Agents Chemother, 47, 2208–16
   PubMed Web of Science ®Google Scholar
• Moretti S, Bozza S, D’Angelo C, et al. (2012). Role of innate immune receptors in paradoxical caspofungin activity in vivo in preclinical aspergillosis. Antimicrob Agents Chemother, 56, 4268–76
   PubMed Web of Science ®Google Scholar
• Moretti S, Bozza S, Massi-Benedetti C, et al. (2014). An immunomodulatory activity of micafungin in preclinical aspergillosis. J Antimicrob Chemother, 69, 1065–74
   PubMed Web of Science ®Google Scholar
• Moriyama B, Gordon LA, McCarthy M, et al. (2014). Emerging drugs and vaccines for candidemia. Mycoses, 57, 718–33
   PubMed Web of Science ®Google Scholar
• Mukherjee J, Scharff MD, Casadevall A. (1992). Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect Immun, 60, 4534–41
   PubMed Web of Science ®Google Scholar
• Munoz JE, Luft VD, Amorim J, et al. (2014). Immunization with P10 peptide increases specific immunity and protects immunosuppressed BALB/c mice infected with virulent yeasts of Paracoccidioides brasiliensis. Mycopathologia, 178, 177–88
   PubMed Web of Science ®Google Scholar
• Nett RJ, Skillman D, Riek L, et al. (2015). Histoplasmosis in Idaho and Montana, USA, 2012-2013. Emerg Infect Dis, 21, 1071–2
   PubMed Web of Science ®Google Scholar
• Nimrichter L, Barreto-Bergter E, Mendonca-Filho RR, et al. (2004). A monoclonal antibody to glucosylceramide inhibits the growth of Fonsecaea pedrosoi and enhances the antifungal action of mouse macrophages. Microbes Infect, 6, 657–65
   PubMed Web of Science ®Google Scholar
• Nooney L, Matthews RC, Burnie JP. (2005). Evaluation of Mycograb, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies. Diagn Microbiol Infect Dis, 51, 19–29
   PubMed Web of Science ®Google Scholar
• Nosanchuk JD, Steenbergen JN, Shi L, et al. (2003). Antibodies to a cell surface histone-like protein protect against Histoplasma capsulatum. J Clin Invest, 112, 1164–75
   PubMed Web of Science ®Google Scholar
• O’Keefe SJ, Tamura J, Kincaid RL, et al. (1992). FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin. Nature, 357, 692–4
   PubMed Web of Science ®Google Scholar
• O’Meara TR, Alspaugh JA. (2012). The Cryptococcus neoformans capsule: A sword and a shield. Clin Microbiol Rev, 25, 387–408
   PubMed Web of Science ®Google Scholar
• Orsborn KI, Shubitz LF, Peng T, et al. (2006). Protein expression profiling of Coccidioides posadasii by two-dimensional differential in-gel electrophoresis and evaluation of a newly recognized peroxisomal matrix protein as a recombinant vaccine candidate. Infect Immun, 74, 1865–72
   PubMed Web of Science ®Google Scholar
• Pachl J, Svoboda P, Jacobs F, et al. (2006). A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis, 42, 1404–13
   PubMed Web of Science ®Google Scholar
• Pagano L, Valentini CG, Fianchi L, Caira M. (2009). The role of neutrophils in the development and outcome of zygomycosis in haematological patients. Clin Microbiol Infect, 15, 33–6
   PubMed Web of Science ®Google Scholar
• Paulovicova E, Machova E, Tulinska J, Bystricky S. (2007). Cell and antibody mediated immunity induced by vaccination with novel Candida dubliniensis mannan immunogenic conjugate. Int immunopharmacol, 7, 1325–33
   PubMed Web of Science ®Google Scholar
• Pereira HA, Tsyshevskaya-Hoover I, Hinsley H, et al. (2010). Candidacidal activity of synthetic peptides based on the antimicrobial domain of the neutrophil-derived protein, CAP37. Med Mycol, 48, 263–72
   PubMed Web of Science ®Google Scholar
• Petraitis V, Petraitiene R, Kelaher AM, et al. (2004). Efficacy of PLD-118, a novel inhibitor of candida isoleucyl-tRNA synthetase, against experimental oropharyngeal and esophageal candidiasis caused by fluconazole-resistant C. albicans. Antimicrob Agents Chemother, 48, 3959–67
   PubMed Web of Science ®Google Scholar
• Pietrella D, Rachini A, Torosantucci A, et al. (2010). A beta-glucan-conjugate vaccine and anti-beta-glucan antibodies are effective against murine vaginal candidiasis as assessed by a novel in vivo imaging technique. Vaccine, 28, 1717–25
   PubMed Web of Science ®Google Scholar
• Pirofski LA, Casadevall A. (2008). The damage-response framework of microbial pathogenesis and infectious diseases. Adv Exp Med Biol, 635, 135–46
   PubMed Web of Science ®Google Scholar
• Pirofski LA, Casadevall A. (2015). What is infectiveness and how is it involved in infection and immunity? BMC Immunol, 16, 13
   PubMed Web of Science ®Google Scholar
• Polonelli L, Beninati C, Teti G, et al. (2014). Yeast killer toxin-like candidacidal Ab6 antibodies elicited through the manipulation of the idiotypic cascade. PloS One, 9, e105727
   Google Scholar
• Polonelli L, Magliani W, Conti S, et al. (2003). Therapeutic activity of an engineered synthetic killer antiidiotypic antibody fragment against experimental mucosal and systemic candidiasis. Infect Immun, 71, 6205–12
   PubMed Web of Science ®Google Scholar
• Polonelli L, Seguy N, Conti S, et al. (1997). Monoclonal yeast killer toxin-like candidacidal anti-idiotypic antibodies. Clin Diagn Lab Immunol, 4, 142–6
   PubMedGoogle Scholar
• Quezada G, Koshkina NV, Zweidler-McKay P, et al. (2008). Intranasal granulocyte-macrophage colony-stimulating factor reduces the Aspergillus burden in an immunosuppressed murine model of pulmonary aspergillosis. Antimicrob Agents Chemother, 52, 716–18
   PubMed Web of Science ®Google Scholar
• Rachini A, Pietrella D, Lupo P, et al. (2007). An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo. Infect Immun, 75, 5085–94
   PubMed Web of Science ®Google Scholar
• Ramadan G, Davies B, Kurup VP, Keever-Taylor CA. (2005). Generation of cytotoxic T cell responses directed to human leucocyte antigen Class I restricted epitopes from the Aspergillus f16 allergen. Clin Exp Immunol, 140, 81–91
   PubMed Web of Science ®Google Scholar
• Rambach G, Blum G, Latgé J-P, et al. (2015). Identification of Aspergillus fumigatus surface components that mediate interaction of conidia and hyphae with human platelets. J Infect Dis, 212, 1140–9
   PubMed Web of Science ®Google Scholar
• Raval RR, Sharabi AB, Walker AJ, et al. (2014). Tumor immunology and cancer immunotherapy: Summary of the 2013 SITC primer. J Immunother Cancer, 2, 14
   PubMedGoogle Scholar
• Razonable RR, Henault M, Lee LN, et al. (2005a). Secretion of proinflammatory cytokines and chemokines during amphotericin B exposure is mediated by coactivation of toll-like receptors 1 and 2. Antimicrob Agents Chemother, 49, 1617–21
   PubMed Web of Science ®Google Scholar
• Razonable RR, Henault M, Watson HL, Paya CV. (2005b). Nystatin induces secretion of interleukin (IL)-1beta, IL-8, and tumor necrosis factor alpha by a toll-like receptor-dependent mechanism. Antimicrob Agents Chemother, 49, 3546–9
   PubMed Web of Science ®Google Scholar
• Ribeiro AM, Bocca AL, Amaral AC, et al. (2010). HSP65 DNA as therapeutic strategy to treat experimental paracoccidioidomycosis. Vaccine, 28, 1528–34
   PubMed Web of Science ®Google Scholar
• Rivera J, Casadevall A. (2005). Mouse genetic background is a major determinant of isotype-related differences for antibody-mediated protective efficacy against Cryptococcus neoformans. J Immunol, 174, 8017–26
   PubMed Web of Science ®Google Scholar
• Rodrigues ML, Travassos LR, Miranda KR, et al. (2000). Human antibodies against a purified glucosylceramide from Cryptococcus neoformans inhibit cell budding and fungal growth. Infect Immun, 68, 7049–60
   PubMed Web of Science ®Google Scholar
• Roilides E, Holmes A, Blake C, et al. (1993). Impairment of neutrophil antifungal activity against hyphae of Aspergillus fumigatus in children infected with human immunodeficiency virus. J Infect Dis, 167, 905–11
   PubMed Web of Science ®Google Scholar
• Rosas AL, Nosanchuk JD, Casadevall A. (2001). Passive immunization with melanin-binding monoclonal antibodies prolongs survival of mice with lethal Cryptococcus neoformans infection. Infect Immun, 69, 3410–12
   PubMed Web of Science ®Google Scholar
• Rossi DC, Munoz JE, Carvalho DD, et al. (2012). Therapeutic use of a cationic antimicrobial peptide from the spider Acanthoscurria gomesiana in the control of experimental candidiasis. BMC Microbiol, 12, 28
   PubMedGoogle Scholar
• Ruan S, McKinley L, Zheng M, et al. (2008). Interleukin-12 and host defense against murine Pneumocystis pneumonia. Infect Immun, 76, 2130–7
   PubMed Web of Science ®Google Scholar
• Sachs UJ, Reiter A, Walter T, et al. (2006). Safety and efficacy of therapeutic early onset granulocyte transfusions in pediatric patients with neutropenia and severe infections. Transfusion, 46, 1909–14
   PubMed Web of Science ®Google Scholar
• Safdar A, Rodriguez GH, Lichtiger B, et al. (2006). Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions. Cancer, 106, 2664–71
   PubMed Web of Science ®Google Scholar
• Salvenmoser S, Seidler MJ, Dalpke A, Muller FM. (2010). Effects of caspofungin, Candida albicans and Aspergillus fumigatus on toll-like receptor 9 of GM-CSF-stimulated PMNs. FEMS Immunol Med Microbiol, 60, 74–7
   PubMed Web of Science ®Google Scholar
• Sandini S, La Valle R, Deaglio S, et al. (2011). A highly immunogenic recombinant and truncated protein of the secreted aspartic proteases family (rSap2t) of Candida albicans as a mucosal anticandidal vaccine. FEMS Immunol Med Microbiol, 62, 215–24
   PubMed Web of Science ®Google Scholar
• Sanford JE, Lupan DM, Schlageter AM, Kozel TR. (1990). Passive immunization against Cryptococcus neoformans with an isotype-switch family of monoclonal antibodies reactive with cryptococcal polysaccharide. Infect Immun, 58, 1919–23
   PubMed Web of Science ®Google Scholar
• Sau K, Mambula SS, Latz E, et al. (2003). The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CD14-dependent mechanism. J Biol Chem, 278, 37561–8
   PubMed Web of Science ®Google Scholar
• Saville SP, Lazzell AL, Chaturvedi AK, et al. (2009). Efficacy of a genetically engineered Candida albicans tet-NRG1 strain as an experimental live attenuated vaccine against hematogenously disseminated candidiasis. Clin Vaccine Immunol CVI, 16, 430–2
   PubMed Web of Science ®Google Scholar
• Scheckelhoff MR, Deepe GS, Jr. (2006). Pulmonary V beta 4+ T cells from Histoplasma capsulatum-infected mice respond to a homologue of Sec31 that confers a protective response. J Infect Dis, 193, 888–97
   PubMed Web of Science ®Google Scholar
• Schmidtchen A, Pasupuleti M, Morgelin M, et al. (2009). Boosting antimicrobial peptides by hydrophobic oligopeptide end tags. J Biol Chem, 284, 17584–94
   PubMed Web of Science ®Google Scholar
• Seguy N, Cailliez JC, Delcourt P, et al. (1997). Inhibitory effect of human natural yeast killer toxin-like candidacidal antibodies on Pneumocystis carinii. Molecular Medicine, 3, 544–52
   PubMed Web of Science ®Google Scholar
• Seidel MG, Minkov M, Witt V, et al. (2009). Granulocyte transfusions in children and young adults: Does the dose matter? J Pediatr Hematol Oncol, 31, 166–72
   PubMed Web of Science ®Google Scholar
• Selvakumar D, Miyamoto M, Furuichi Y, Komiyama T. (2006a). Inhibition of fungal beta-1,3-glucan synthase and cell growth by HM-1 killer toxin single-chain anti-idiotypic antibodies. Antimicrob Agents Chemother, 50, 3090–7
   PubMed Web of Science ®Google Scholar
• Selvakumar D, Miyamoto M, Furuichi Y, Komiyama T. (2006b). Inhibition of beta-1,3-glucan synthase and cell growth of Cryptococcus species by recombinant single-chain anti-idiotypic antibodies. J Antibiot, 59, 73–9
   PubMed Web of Science ®Google Scholar
• Selvakumar D, Zhang QZ, Miyamoto M, et al. (2006c). Identification and characterization of a neutralizing monoclonal antibody for the epitope on HM-1 killer toxin. J Biochem, 139, 399–406
   PubMed Web of Science ®Google Scholar
• Sevilla MJ, Robledo B, Rementeria A, et al. (2006). A fungicidal monoclonal antibody protects against murine invasive candidiasis. Infect Immun, 74, 3042–5
   PubMed Web of Science ®Google Scholar
• Shi D, Li D, Yin Q, et al. (2015). Silenced suppressor of cytokine signaling 1 (SOCS1) enhances the maturation and antifungal immunity of dendritic cells in response to Candida albicans in vitro. Immunol Res, 61, 206–18
   PubMed Web of Science ®Google Scholar
• Simitsopoulou M, Roilides E, Paliogianni F, et al. (2008). Immunomodulatory effects of voriconazole on monocytes challenged with Aspergillus fumigatus: Differential role of Toll-like receptors. Antimicrob Agents Chemother, 52, 3301–6
   PubMed Web of Science ®Google Scholar
• Specht CA, Nong S, Dan JM, et al. (2007). Contribution of glycosylation to T cell responses stimulated by recombinant Cryptococcus neoformans mannoprotein. J Infect Dis, 196, 796–800
   PubMed Web of Science ®Google Scholar
• Spellberg B, Ibrahim AS, Lin L, et al. (2008). Antibody titer threshold predicts anti-candidal vaccine efficacy even though the mechanism of protection is induction of cell-mediated immunity. J Infect Dis, 197, 967–71
   PubMed Web of Science ®Google Scholar
• Spellberg B. (2011). Vaccines for invasive fungal infections. F1000 Med Rep, 3, 13
   PubMedGoogle Scholar
• Spellberg BJ, Collins M, Avanesian V, et al. (2007). Optimization of a myeloid cell transfusion strategy for infected neutropenic hosts. J Leukoc Biol, 81, 632–41
   PubMed Web of Science ®Google Scholar
• Steinbach WJ, Schell WA, Blankenship JR, et al. (2004). In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus. Antimicrob Agents Chemother, 48, 1664–9
   PubMed Web of Science ®Google Scholar
• Stuehler C, Khanna N, Bozza S, et al. (2011). Cross-protective TH1 immunity against Aspergillus fumigatus and Candida albicans. Blood, 117, 5881–91
   PubMed Web of Science ®Google Scholar
• Stuehler C, Nowakowska J, Bernardini C, et al. (2015). Multispecific Aspergillus T cells selected by CD137 or CD154 induce protective immune responses against the most relevant mold infections. J Infect Dis, 211, 1251–61
   PubMed Web of Science ®Google Scholar
• Sun Z, Zhu P, Li L, et al. (2012). Adoptive immunity mediated by HLA-A*0201 restricted Asp f16 peptides-specific CD8+ T cells against Aspergillus fumigatus infection. Eur J Clin Microbiol Infect Dis, 31, 3089–96
   PubMed Web of Science ®Google Scholar
• Sung WS, Lee DG. (2008). Pleurocidin-derived antifungal peptides with selective membrane-disruption effect. BiochemBiophys Res Commun, 369, 858–61
   PubMed Web of Science ®Google Scholar
• Sutherland A, Ellis D. (2008). Treatment of a critically ill child with disseminated Candida glabrata with a recombinant human antibody specific for fungal heat shock protein 90 and liposomal amphotericin B, caspofungin, and voriconazole. Pediatr Crit Care Med, 9, e23–5
   PubMedGoogle Scholar
• Svirshchevskaya E, Frolova E, Alekseeva L, et al. (2000). Intravenous injection of major and cryptic peptide epitopes of ribotoxin, Asp f 1 inhibits T cell response induced by crude Aspergillus fumigatus antigens in mice. Peptides, 21, 1–8
   PubMed Web of Science ®Google Scholar
• Taborda CP, Rivera J, Zaragoza O, Casadevall A. (2003). More is not necessarily better: Prozone-like effects in passive immunization with IgG. J Immunol, 170, 3621–30
   PubMed Web of Science ®Google Scholar
• Tarcha EJ, Basrur V, Hung CY, et al. (2006). A recombinant aspartyl protease of Coccidioides posadasii induces protection against pulmonary coccidioidomycosis in mice. Infect Immun, 74, 516–27
   PubMed Web of Science ®Google Scholar
• Theus SA, Smulian AG, Steele P, et al. (1998). Immunization with the major surface glycoprotein of Pneumocystis carinii elicits a protective response. Vaccine, 16, 1149–57
   PubMed Web of Science ®Google Scholar
• Thornton CR. (2014). Breaking the mould – novel diagnostic and therapeutic strategies for invasive pulmonary aspergillosis in the immune deficient patient. Expert Rev Clin Immunol, 10, 771–80
   PubMed Web of Science ®Google Scholar
• Torosantucci A, Bromuro C, Chiani P, et al. (2005). A novel glyco-conjugate vaccine against fungal pathogens. J Exp Med, 202, 597–606
   PubMed Web of Science ®Google Scholar
• Torosantucci A, Chiani P, Bromuro C, et al. (2009). Protection by anti-beta-glucan antibodies is associated with restricted beta-1,3 glucan binding specificity and inhibition of fungal growth and adherence. PloS One, 4, e5392
   PubMed Web of Science ®Google Scholar
• Tramsen L, Schmidt S, Boenig H, et al. (2013). Clinical-scale generation of multi-specific anti-fungal T cells targeting Candida, Aspergillus and mucormycetes. Cytotherapy, 15, 344–51
   PubMed Web of Science ®Google Scholar
• Tramsen L, Schmidt S, Roeger F, et al. (2014). Immunosuppressive compounds exhibit particular effects on functional properties of human anti-Aspergillus Th1 cells. Infect Immun, 82, 2649–56
   PubMed Web of Science ®Google Scholar
• Travassos LR, Silva LS, Rodrigues EG, et al. (2004). Therapeutic activity of a killer peptide against experimental paracoccidioidomycosis. J Antimicrob Chemother, 54, 956–8
   PubMed Web of Science ®Google Scholar
• Tsai H, Bobek LA. (1998). Human salivary histatins: Promising anti-fungal therapeutic agents. Crit Rev Oral Biol Med, 9, 480–97
   PubMedGoogle Scholar
• Twaroch TE, Curin M, Valenta R, Swoboda I. (2015). Mold allergens in respiratory allergy: From structure to therapy. Allergy, asthma & Immunol Res, 7, 205–20
   PubMed Web of Science ®Google Scholar
• Unsinger J, Burnham CA, McDonough J, et al. (2012). Interleukin-7 ameliorates immune dysfunction and improves survival in a 2-hit model of fungal sepsis. J Infect Dis, 206, 606–16
   PubMed Web of Science ®Google Scholar
• Vallon-Eberhard A, Makovitzki A, Beauvais A, et al. (2008). Efficient clearance of Aspergillus fumigatus in murine lungs by an ultrashort antimicrobial lipopeptide, palmitoyl-lys-ala-DAla-lys. Antimicrob Agents Chemother, 52, 3118–26
   PubMed Web of Science ®Google Scholar
• Vazquez JA, Hidalgo JA, De Bono S. (2000). Use of sargramostim (rh-GM-CSF) as adjunctive treatment of fluconazole-refractory oropharyngeal candidiasis in patients with AIDS: A pilot study. HIV Clin Trials, 1, 23–9
   PubMedGoogle Scholar
• Venturini J, Cavalcante RS, Golim Mde A, et al. (2014). Phenotypic and functional evaluations of peripheral blood monocytes from chronic-form paracoccidioidomycosis patients before and after treatment. BMC Infect Dis, 14, 552
   PubMedGoogle Scholar
• Vickers AE, Meyer E, Dannecker R, et al. (1995). Human liver cytochrome P4503A biotransformation of the cyclosporin derivative SDZ IMM 125. Drug Metab Dispos, 23, 321–6
   PubMed Web of Science ®Google Scholar
• Viejo-Diaz M, Andres MT, Fierro JF. (2005). Different anti-Candida activities of two human lactoferrin-derived peptides, Lfpep and kaliocin-1. Antimicrob Agents Chemother, 49, 2583–8
   PubMed Web of Science ®Google Scholar
• Viudes A, Lazzell A, Perea S, et al. (2004). The C-terminal antibody binding domain of Candida albicans mp58 represents a protective epitope during candidiasis. FEMS Microbiol Lett, 232, 133–8
   PubMed Web of Science ®Google Scholar
• Vora S, Purimetla N, Brummer E, Stevens DA. (1998). Activity of voriconazole, a new triazole, combined with neutrophils or monocytes against Candida albicans: Effect of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. Antimicrob Agents Chemother, 42, 907–10
   PubMed Web of Science ®Google Scholar
• Wang CW, Yip BS, Cheng HT, et al. (2009). Increased potency of a novel D-beta-naphthylalanine-substituted antimicrobial peptide against fluconazole-resistant fungal pathogens. FEMS Yeast Res, 9, 967–70
   PubMed Web of Science ®Google Scholar
• Wang H, LeBert V, Hung CY, et al. (2014a). C-type lectin receptors differentially induce th17 cells and vaccine immunity to the endemic mycosis of North America. J Immunol, 192, 1107–19
   PubMed Web of Science ®Google Scholar
• Wang H, Wu Y, Fu R, et al. (2014b). Granulocyte transfusion combined with granulocyte colony stimulating factor in severe infection patients with severe aplastic anemia: A single center experience from China. PloS One, 9, e88148
   Google Scholar
• Weinblatt ME, Kremer JM, Bankhurst AD, et al. (1999). A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med, 340, 253–9
   PubMed Web of Science ®Google Scholar
• Wells J, Gigliotti F, Simpson-Haidaris PJ, Haidaris CG. (2004). Epitope mapping of a protective monoclonal antibody against Pneumocystis carinii with shared reactivity to Streptococcus pneumoniae surface antigen PspA. Infect Immun, 72, 1548–56
   PubMed Web of Science ®Google Scholar
• Wells J, Haidaris CG, Wright TW, Gigliotti F. (2006). Active immunization against Pneumocystis carinii with a recombinant P. carinii antigen. Infect Immun, 74, 2446–8
   PubMed Web of Science ®Google Scholar
• Wildbaum G, Shahar E, Katz R, et al. (2013). Continuous G-CSF therapy for isolated chronic mucocutaneous candidiasis: Complete clinical remission with restoration of IL-17 secretion. J Allergy Clin Immunol, 132, 761–4
   PubMed Web of Science ®Google Scholar
• Wuthrich M, Filutowicz HI, Allen HL, et al. (2007). V beta1 + J beta1.1+/V alpha2+ J alpha49+ CD4+ T cells mediate resistance against infection with Blastomyces dermatitidis. Infect Immun, 75, 193–200
   PubMed Web of Science ®Google Scholar
• Wuthrich M, Filutowicz HI, Klein BS. (2000). Mutation of the WI-1 gene yields an attenuated blastomyces dermatitidis strain that induces host resistance. J Clin Invest, 106, 1381–9
   PubMed Web of Science ®Google Scholar
• Wuthrich M, Filutowicz HI, Warner T, et al. (2003). Vaccine immunity to pathogenic fungi overcomes the requirement for CD4 help in exogenous antigen presentation to CD8+ T cells: Implications for vaccine development in immune-deficient hosts. J Exp Med, 197, 1405–16
   PubMed Web of Science ®Google Scholar
• Wuthrich M, Gern B, Hung CY, et al. (2011). Vaccine-induced protection against 3 systemic mycoses endemic to North America requires Th17 cells in mice. J Clin Invest, 121, 554–68
   PubMed Web of Science ®Google Scholar
• Xin H, Cutler JE. (2011). Vaccine and monoclonal antibody that enhance mouse resistance to candidiasis. Clin Vaccine Immunol, 18, 1656–67
   PubMed Web of Science ®Google Scholar
• Xing T, Zhong L, Qiu G, et al. (2014). Evolution of CD4(+)CD25(hi) T cell subsets in Aspergillus-infected liver transplantation recipients reduces the incidence of transplantation rejection via upregulating the production of anti-inflammatory cytokines. Genet Mol Res, 13, 4932–9
   PubMed Web of Science ®Google Scholar
• Yang R, Liu Y, Kelk P, et al. (2013). A subset of IL-17(+) mesenchymal stem cells possesses anti-Candida albicans effect. Cell Res, 23, 107–21
   PubMed Web of Science ®Google Scholar
• Zaragoza O, Rodrigues ML, De Jesus M, et al. (2009). The capsule of the fungal pathogen Cryptococcus neoformans. Adv Appl Microbiol, 68, 133–216
   PubMed Web of Science ®Google Scholar
• Zhang G, Wu H, Ross CR, et al. (2000). Cloning of porcine NRAMP1 and its induction by lipopolysaccharide, tumor necrosis factor alpha, and interleukin-1beta: Role of CD14 and mitogen-activated protein kinases. Infect Immun, 68, 1086–93
   PubMed Web of Science ®Google Scholar
• Zhou Q, Gault RA, Kozel TR, Murphy WJ. (2006). Immunomodulation with CD40 stimulation and interleukin-2 protects mice from disseminated cryptococcosis. Infect Immun, 74, 2161–8
   PubMed Web of Science ®Google Scholar
• Zhou Q, Gault RA, Kozel TR, Murphy WJ. (2007). Protection from direct cerebral cryptococcus infection by interferon-gamma-dependent activation of microglial cells. J Immunol, 178, 5753–61
   PubMed Web of Science ®Google Scholar
• Zhu F, Ramadan G, Davies B, et al. (2008). Stimulation by means of dendritic cells followed by Epstein-Barr virus-transformed B cells as antigen-presenting cells is more efficient than dendritic cells alone in inducing Aspergillus f16-specific cytotoxic T cell responses. Clin Exp Immunol, 151, 284–96
   PubMed Web of Science ®Google Scholar